|
|
|
Selpercatinib (12)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Thyroid carcinoma, RET-fusion-positive, refractory to radioactive iodine, ≥ 2 years
|
n.d.
|
active procedure
|
|
|
|
Selpercatinib (11)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Solid tumours, RET-fusion-positive, aged ≥ 2 to < 18 years
|
n.d.
|
active procedure
|
|
|
|
Selpercatinib (10)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
RET-mutated medullary thyroid carcinoma (MTC), ≥ 2 years
|
n.d.
|
active procedure
|
|
|
|
Selpercatinib (9)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Non-small cell lung cancer, RET-fusion+, first-line treatment
|
155–270
|
100%
additional benefit not proven
|
|
|
|
Selpercatinib (8)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Thyroid carcinoma, RET-mutated, monotherapy, from 12 years of age
|
40–170
|
100%
Indication of
major additional benefit
|
|
|
|
Selpercatinib (7)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Solid tumors, RET-Fusion+
|
59–159
|
100%
additional benefit not proven
|
|
|
|
Selpercatinib (6)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Thyroid carcinoma, RET fusion+, refractory to radioiodine, first-line or after systemic prior therapy, ≥ 12 years of age
|
6–36
|
100%
additional benefit not proven
|
|
|
|
Selpercatinib (5)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Thyroid carcinoma (MTC), RET-mutated, monotherapy, 12 years and older
|
0
40–170
|
100%
additional benefit not proven
repealed
|
|
|
|
Selpercatinib (4)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Non-small cell lung cancer (NSCLC), RET fusion+, first-line
|
0
115–310
|
100%
additional benefit not proven
repealed
|
|
|
|
Selpercatinib (3)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Thyroid carcinoma (MTC), RET fusion+, after sorafenib and/or lenvatinib pre-therapy
|
2–16
|
100%
additional benefit not proven
|
|
|
|
Selpercatinib (2)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Medullary thyroid carcinoma (MTC), RET-mutated, after cabozantinib and/or vandetanib prior therapy, ≥ 12 years
|
5–80
|
100%
additional benefit not proven
|
|
|
|
Selpercatinib (1)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Non-small cell lung carcinoma (NSCLC), RET fusion+, after platinum-based chemotherapy and/or immunotherapy
|
55–200
|
100%
additional benefit not proven
|
